ARTICLE | Company News
Spectral, Elan end assay deal
July 18, 2003 7:00 AM UTC
Spectral Diagnostics (TSE:SDI) and ELN ended their 1998 deal to develop and commercialize sepsis assays, including SDI's Endotoxin Activity Assay (EAA), which is approved to identify patients at risk ...